1. Home
  2. TLIH vs BLRX Comparison

TLIH vs BLRX Comparison

Compare TLIH & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TLIH

Ten-League International Holdings Limited Ordinary Shares

N/A

Current Price

$0.39

Market Cap

11.8M

Sector

N/A

ML Signal

N/A

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

HOLD

Current Price

$3.02

Market Cap

12.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TLIH
BLRX
Founded
1998
2003
Country
Singapore
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
12.6M
IPO Year
2025
2011

Fundamental Metrics

Financial Performance
Metric
TLIH
BLRX
Price
$0.39
$3.02
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$19.00
AVG Volume (30 Days)
691.4K
17.2K
Earning Date
09-30-2025
11-24-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.10
N/A
Revenue
$51,204,304.00
$12,735,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.51
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$2.30
52 Week High
$7.00
$7.77

Technical Indicators

Market Signals
Indicator
TLIH
BLRX
Relative Strength Index (RSI) 41.05 44.84
Support Level $0.39 $2.99
Resistance Level $0.67 $3.18
Average True Range (ATR) 0.07 0.18
MACD -0.01 0.01
Stochastic Oscillator 2.31 43.75

Price Performance

Historical Comparison
TLIH
BLRX

About TLIH Ten-League International Holdings Limited Ordinary Shares

Ten-League International Holdings Ltd is a Singapore-based provider of turnkey project solutions. Its business consists of sales of heavy equipment and parts, heavy equipment rental and provision of engineering consultancy services to port, construction, civil engineering and underground foundation industries. It currently conducts its operations through its wholly-owned subsidiaries. The equipment it provides is organized into four categories based on their functions and application scenarios, namely, foundation equipment, hoist equipment, excavation equipment and port machinery. The company operates in Singapore and Other International Countries.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: